Imagine a future where preventable health crises could be stopped before they even begin. That's the bold vision behind a growing call for New Zealand's drug funding agency, Pharmac, to approve a weight loss medication for teenagers. But here's where it gets controversial: while the drug, Wegovy, has shown promise, its high cost and long-term implications spark heated debate. Is this a lifeline for teens battling severe obesity, or a slippery slope toward dependency on medication? Let’s dive in.
A leading pediatric endocrinologist, Professor Wayne Cutfield from the Liggins Institute, is championing this cause. He argues that funding Wegovy for teens could be a game-changer in preventing life-threatening conditions like heart disease, diabetes, and liver sclerosis. Cutfield paints a stark picture: teenagers as young as 14 weighing between 120 and 150 kilograms, gaining up to a kilogram each month. Without intervention, these teens face a future riddled with obesity-related complications. And this is the part most people miss: failing to act now, Cutfield warns, is like ‘closing the gate after the horse has bolted.’
Wegovy, a semaglutide-based drug, has been available in New Zealand since July last year, costing around $460 per month. Pharmac’s advisory panel has provisionally recommended funding it for chronic weight management in individuals with high BMIs and associated health conditions. However, the recommendation comes with strings attached—Special Authority criteria will restrict who can prescribe it. The full details of this decision are expected by March, but Cutfield is already sounding the alarm for teens.
Here’s the catch: while Wegovy suppresses appetite and aids weight loss, real-world data shows that weight regain is common once the drug is stopped. Cutfield emphasizes that the drug alone isn’t a silver bullet. ‘Unless patients make lifestyle changes—learning to eat less, adopting healthier diets, and increasing physical activity—they may need treatment for life,’ he warns. This raises questions about sustainability and whether the drug addresses the root causes of obesity.
Pharmac’s director of device and assessment, Dr. David Hughes, notes that age is typically not a deciding factor in funding decisions unless there’s strong clinical evidence to support it. Pharmac has already received two funding applications for Wegovy: one for individuals with cardiovascular disease and a BMI of 27 or higher, and another for chronic weight management in those with a BMI of 30 or higher and related comorbidities. The final decision is expected in March 2026.
But here’s the bigger question: At $460 a month, is Wegovy accessible to all who need it? Cutfield highlights the ‘equity issue’ surrounding its cost, arguing that the long-term benefits—preventing costly diseases and hospitalizations—far outweigh the expense. Yet, critics wonder if this is a sustainable solution or if it shifts the focus away from addressing societal and environmental factors driving obesity.
New Zealand has the third-highest adult obesity rate in the OECD, making this debate particularly urgent. While Cutfield advocates for a dual approach—medication paired with lifestyle changes—he stresses that healthcare providers must work harder to wean patients off the drug over time. ‘We can’t let them stay on this for life,’ he says.
What do you think? Is funding Wegovy for teens a necessary step toward preventing obesity-related diseases, or does it risk creating a dependency on costly medication? Should the focus be more on systemic changes to tackle obesity at its roots? Share your thoughts in the comments—this is a conversation that needs your voice.
